Nick Georgitseas

EY’s latest analysis of 50 pharmaceutical and life sciences companies shows a sharp acceleration of enabling and core functions over the last five years. The numbers speak for themselves: 45% penetration in drug discovery & development 60% in regulatory affairs 54% in medical affairs 50% in commercial operations GCCs in India are no longer just about cost efficiency — they are anchoring the most critical, knowledge-intensive work at the intersection of talent and technology, driving innovation across the entire life sciences value chain. I recently spoke with Shilpa Phadnis from The Times of India about this transformation. A big thank you to Sonam Mahajan and Nikhil Kumar for your support on this report. Click here to read more : https://lnkd.in/grnztsjE Our complete report: https://lnkd.in/gvpystxD Tarannum Khan Sayan Banerjee Ajay Kamat Vijay Shankar Kunal Ghatak Alpana Dutta Ritika Loganey Gupta Rashmi Kumat Sunil Venkatesh Anand Rao Manikandan Balasubramanian Shiv Narain #ShapeTheFutureWithConfidence #GCC #LifeSciences

152

2 Comments

In BCG’s latest survey, approximately 25% of biopharma and 10% of medtech companies reported at least 5% cost reductions and revenue gains from GenAI. While this is promising, it also underlines the struggle to derive value at scale from this fascinating technology. This article highlights some notable opportunities in three high-value plays: deploying AI agents to assist on the shop floor, reshaping regulatory and quality reporting, and reinventing tech transfer to cut variability and timelines. For manufacturers that scale, 2025 could deliver more operational value than the past three years combined. Our research breaks down how leaders can capture this opportunity at scale 👉: https://lnkd.in/d5G_TZhG #GenAI #HealthCareOperations #Biopharma #MedTech

48

A few weeks after the Life Sciences Conference, one takeaway from our Agentic AI session continues to resonate in conversations across the industry: Adoption is no longer the challenge, impact is. We’ve reached a point where many companies are experimenting with GenAI and agentic tools, but too few are seeing measurable business outcomes. The real value is coming from those who are moving beyond experimentation to reimagine how work gets done, aiming not for 3% improvements, but for 30–50% step changes in performance. What stood out in the discussion during our conference was how quickly the conversation shifts when teams are given bold targets and the space to challenge legacy ways of working. We heard compelling examples from companies who are using agents to speed up regulatory processes, streamline field insights, and unlock supply chain efficiencies -- not in theory, but in practice. Another critical theme: building AI fluency across the enterprise. That doesn’t mean everyone becomes a developer -- it means people across roles understand what AI can do and how to lead change with it. For many, that’s where the real scaling begins. This is still a learning journey for the industry. But the organizations combining bold ambition, smart prioritization, and deep investment in people are already starting to pull ahead. #LifeSciences #AIFluency #AgenticAI #McKinsey 

125

6 Comments

Why does people resilience matter in times of disruption? When people are empowered, organizations become more adaptive, more agile and better positioned to thrive amid future volatility. Our latest research outlines key actions companies should take when putting people first to build lasting enterprise resilience. Read on: https://accntu.re/4lwnERF​ #People #Workforce #Accenture

43

"Brain health and brain skills are going to be at the center of economic vitality and competitiveness in future, so CEOs are starting to understand that there is a competitive advantage and real value from investing in this space,” Erica Hutchins Coe, Global Executive Director of the McKinsey Health Institute. The latest from The Innovator's Editor in Chief Jennifer Schenker explores why the transition to the brain economy is the "New New Thing" that will enable communities, societies, and economies to thrive. Read it here: https://lnkd.in/djDp-4Z5 #BrainEconomy #BrainHealth #InvestInMentalHealth

35

1 Comment

In Accenture’s “Reinventing R&D in the Age of AI,” dynamic portfolio management emerged as one of four critical capabilities necessary for gaining a competitive edge in the industry. Therefore, we conducted brand new research to dive deeper into this vital topic. These new findings, coupled with our original research, underscore the urgent need for reinvention towards dynamic portfolio management. 

74

1 Comment